Meet The Team

Brinks DEA Consulting Selects Only the Most Qualified Consultants with Extensive Experience

DEA Compliance, DEA Consulting, DEA Inspections, DEA Regulations

Scott A. Brinks

Founder/Chief Consultant

Scott Brinks, owner of Brinks DEA Consulting, is a nationally recognized authority in controlled substance regulation, diversion prevention, and pharmaceutical compliance, backed by 28 years of distinguished federal law enforcement and DEA leadership. His roles included Diversion Investigator, Group Supervisor, Policy Staff Coordinator, and Section Chief for DEA regulatory drafting.

Mr. Brinks began his federal career in 2001 as a Diversion Investigator with the Drug Enforcement Administration (DEA), following prior service as a Military Police Officer in the U.S. Army and a civilian police officer with the Department of Veterans Affairs. He served in the Cleveland Resident Office, where he led complex investigations into pharmaceutical diversion. He later became Group Supervisor in Indiana and Illinois, managing multi-jurisdictional enforcement operations and overseeing teams of investigators.

Mr. Brinks holds a Master of Arts in Pastoral Counseling from Liberty Baptist Theological Seminary and a Bachelor of Arts in Sociology from St. Leo University. His leadership is defined by integrity, innovation, and a commitment to public service.

Click Here to learn more
DEA Compliance, DEA Consulting, DEA Inspections, DEA Regulations

Sarah Boblenz

Senior Consultant

Sarah Boblenz, Senior Consultant for Brinks DEA Consulting, brings over 22 years of DEA experience as a Diversion Investigator, Diversion Group Supervisor, Diversion Program Manager, and Senior Policy Analyst. She specializes in DEA policy, controlled substance investigations, regulatory training, and helping registrants navigate compliance with the Controlled Substances Act.

Mrs. Boblenz is a seasoned regulatory and policy expert with over two decades of distinguished service at the U.S. Drug Enforcement Administration (DEA). Now serving as a Senior Consultant at Brinks Consulting, LLC, she brings unparalleled insight into controlled substances regulation, investigative procedures, and compliance strategies. Her career reflects a deep commitment to public safety, regulatory integrity, and professional excellence.

Mrs. Boblenz holds a Bachelor and Associates Degree from Warburg University.

Her blend of field experience, policy acumen, and educational background makes her an invaluable resource for regulatory guidance and strategic consulting.

dan dormont, dea compliance attorney

Daniel Dormont

General Counsel and Senior Consultant

Mr. Dormont is one of the nation’s leading experts on the regulation of controlled substances. He served for over 30 years as an attorney in the U.S. Department of Justice, Drug Enforcement Administration, and in the U.S. Food and Drug Administration. 

During his career with the Drug Enforcement Administration (DEA), Mr. Dormont advised DEA Administrators, United States Attorneys General, United States Attorneys, and other senior officials within DEA and the Department of Justice on a wide array of criminal, civil, and administrative provisions pertaining to controlled substances.  He wrote numerous provisions of the Controlled Substances Act, DEA regulations, and agency policy documents on topics such as the following:

  • Telemedicine – Prescribing and dispensing of controlled substances by means of the Internet (the Ryan Haight Act)
  • Immediate suspension orders served on DEA registrants
  • Corrective action plans for registrants facing revocation of registration
  • Legitimate medical purpose requirement for prescriptions written by practitioners and the corresponding responsibility of pharmacists
  • Dispensing of controlled substances for the treatment of pain
  • Dispensing of controlled substances at long-term care facilities
  • Dispensing of controlled substances by veterinarians in multiple states
  • Delivery of controlled substances by a pharmacy to the prescribing practitioner
  • Addiction treatment – Administering controlled substances by narcotic treatment programs and hospitals
  • Imports and exports of controlled substances
  • Emergency medical services – registration and handling of controlled substances
  • Research – Applications for schedule I DEA registration
  • Electronic prescriptions for controlled substances
  • Disposal of controlled substances
  • Issuance by practitioners of multiple schedule II prescriptions
  • Scheduling and regulation of anabolic steroids
  • Advertising the sale of controlled substances over the Internet
  • DEA Quotas
  • DEA Scheduling Actions
  • Controls To Enhance the Cultivation of Marijuana for Research in the United States

As an Associate Chief Counsel at the DEA, Mr. Dormont supervised the team of attorneys responsible for reviewing all regulatory matters arising out of the agency’s Diversion Control Division.  He also briefed and argued cases on behalf of the Department of Justice before the United States Court of Appeals.  As an Associate Chief Counsel at the U.S. Food and Drug Administration, Mr. Dormont’s areas of focus included:  shortages of controlled substances and related quota considerations; scheduling of controlled substances; Drug Supply Chain Security Act; and Investigational New Drug Applications (INDs).

Mr. Dormont earned a Bachelor of Arts degree in mathematics from the University of Pennsylvania and a Juris Doctor from Boston College Law School.